Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Rechallenge With Panitumumab Driven by RAS Clonal-mediated Dynamic of Resistance

NCT03227926 is registered in ClinicalTrials.gov with Fondazione del Piemonte per l'Oncologia as lead sponsor.

NCT NCT03227926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03227926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Rechallenge With Panitumumab Driven by RAS Clonal-mediated Dynamic of Resistance
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2017
Completion date
December 31, 2021
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer